Mustang Bio, Inc. was notified of a delisting due to its stock price being below $1.00 for 30 consecutive days, but has been granted extensions to regain compliance until early 2025; additionally, the Interim CFO resigned and was replaced by the current CEO, Dr. Manuel Litchman.